Clinical Trials Update: Sept. 20, 2006
Diabetes - Type 2 Hypertension (High Blood Pressure) T-Cell Lymphoma
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
Diabetes - Type 2
This is a new type of treatment for type 2 diabetes. The treatment under investigation is a pill or capsule, taken each morning, which works by adjusting the body's natural insulin to control blood glucose (sugar) levels.
This may enable you to manage your diabetes more successfully. Adults with type 2 diabetes may qualify for the study. To find out more about this study, go to the PEAK Web site.
Research sites are located across the United States.
Hypertension (High Blood Pressure)
If you or someone you love is overweight, chances of getting high blood pressure increase.
If you are between ages 21 and 75, you might be eligible to participate in a research study of an investigational drug used to treat high blood pressure in overweight adults.
If you qualify, all study-related physical exams, study-related procedures, and study drug will be provided at no cost, and you may be reimbursed for time and travel.
The research site is in St. Louis, Mo.
This is a study to evaluate the safety and effectiveness of pralatrexate when administered with vitamin B12 and folic acid supplements to people with relapsed or refractory peripheral T-cell lymphoma.
Volunteers may be included who have documentation of relapsed-refractory aggressive non-cutaneous peripheral T-cell lymphoma that recurred after at least one prior chemotherapy treatment, and adequate hematological, hepatic, and renal function.
Women qualifying for this study must not be or become pregnant while receiving pralatrexate, and men who are not surgically sterile must agree to practice a medically acceptable contraceptive regimen while receiving pralatrexate.
People with congestive heart failure or uncontrolled hypertension will not qualify.
The research sites are located across the United States.
Copyright 2006 Thomson CenterWatch. All rights reserved.